GleamWall
中文EN

SLXN Silexion Therapeutics Corp

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2022416 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-43.1%
TTM EPS YoY-211.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-266.0%
ROA-143.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets56.5%
Debt / equity0.00x
Current ratio1.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-16.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.29M$2.21M$1.37M$3.38M$2.16M$1.02M$590,000$871,000
SG&A expense$1.40M$1.47M$1.38M$1.03M$1.14M$1.27M$1.06M$1.03M
Operating income-$2.68M-$3.68M-$2.75M-$4.41M-$3.29M-$2.28M-$1.65M-$1.90M
Pretax income-$2.53M-$3.55M-$2.73M-$4.41M-$3.26M-$2.50M-$1.74M-$1.75M
Income tax———$0$0$3,000—$1,000
Net income-$2.53M-$3.55M-$2.73M-$4.41M-$3.26M-$2.50M-$1.74M-$1.75M
EBITDA-$2.68M-$3.68M-$2.75M-$4.40M-$3.29M-$2.28M-$1.65M-$1.91M
EPS (basic)13.705.170.85—691.1443.193.84—
EPS (diluted)13.705.170.85—691.1443.193.84—
Weighted avg. shares (diluted)184,927687,3533.23M—4,72057,952451,990—
Balance sheet
Cash & equivalents$4.76M$2.32M$2.50M$5.99M$9.32M$3.54M$6.23M$1.27M
Current assets$6.11M$3.74M$4.07M$6.64M$11.05M$5.24M$7.72M$2.25M
PP&E, net$21,000$20,000$23,000$25,000$26,000$30,000$32,000$30,000
Total assets$6.83M$4.25M$4.60M$7.21M$11.61M$5.80M$8.31M$2.86M
Current liabilities$3.68M$3.98M$4.06M$2.76M$2.79M$2.15M$2.40M$3.52M
Total liabilities$3.86M$4.20M$4.31M$4.61M$4.64M$5.68M$5.72M$6.85M
Shareholders' equity$2.97M$44,000$291,000$2.60M$6.98M$120,000$2.59M-$3.99M
Shares outstanding603,0551.18M3.13M13,0283.13M579,5368.69M123.29M
Cash flow statement
Operating cash flow-$2.11M-$2.92M-$3.65M-$3.02M-$2.84M-$2.51M-$2.45M-$2.93M
Capital expenditure$42,000$0$0$2,000$0$1,000$6,000$0
Free cash flow-$2.15M-$2.92M-$3.65M-$3.02M-$2.84M-$2.51M-$2.46M-$2.93M
Investing cash flow-$42,000-$1,000$0-$7,000$0-$1,000-$6,000$0
Financing cash flow$4.70M$2.74M$83,000-$221,000$8.62M-$195,000$7.43M$2.18M
Depreciation & amortization$2,000$3,000$2,000$3,000$4,000$3,000$4,000-$12,000
Stock-based compensation$16,000$197,000$345,000$38,000$38,000$37,000$21,000$0

Free plan shows the latest 8 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.